How have you incorporated gene expression profiling tests for melanoma or SCC into your practice and has it changed your approach to treatment and/or monitoring?

This is a controversial topic for sure, but most emerging technologies in medicine are.

I do use gene-expression profiling in the treatment of cutaneous SCC and invasive melanoma. My theoretical framework for using GEP testing is that it is a forward looking test, while clinical staging is backward...

I had a few patients call my office when they saw the cost of these tests on their EOBs. While they themselves didn't have to pay, they weren't happy with the cost of the tests and wondered why I did them, one actually wondering if I was getting a "kickback".

Not once did I have to change my treatme...